- $125.12m
- $114.69m
- $48.07m
- 100
- 36
- 99
- 92
R2019 June 30th | R2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 31.3 | 32.5 | 35.8 | 41.7 | 48.1 |
Cost of Revenue | |||||
Gross Profit | 23.8 | 25.2 | 27.3 | 31.4 | 36.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 28.5 | 27.4 | 32.6 | 38.7 | 44.1 |
Operating Profit | 2.83 | 5.12 | 3.14 | 2.97 | 4.01 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2.92 | 5.24 | 3.17 | 3 | 4.09 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.98 | 4.16 | 2.36 | 2.31 | 3.17 |
Net Income Before Extraordinary Items | |||||
Net Income | 1.98 | 4.16 | 2.36 | 2.31 | 3.17 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 1.98 | 4.16 | 2.36 | 2.31 | 3.17 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.229 | 0.389 | 0.265 | 0.263 | 0.364 |